ABIO - VBL Therapeutics' Cancer Drug And Other News: The Good Bad And Ugly Of Biopharma
VBL Therapeutics reports progress for ovarian cancer drug candidate
VBL Therapeutics (VBLT) announced the progress for its Phase 3 OVAL trial for platinum resistant ovarian cancer. The overall survival data from the trial was unblinded and reviewed by the independent Data Safety Monitoring Committee. This was the second interim analysis carried out by the committee and the continuation of the trial was recommended.
For its second interim analysis, the committee studied unblinded overall survival data of the first 100 randomized patients with a follow-up of at least 3 months. Overall survival is the